Effect of Some Drugs on Liver Fibrosis
Overview
Effect of Some Drugs on Liver Fibrosis
Full Title of Study: “Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: October 2026
Detailed Description
The study aimed at evaluating the effect of Some Drugs on Liver Fibrosis
Interventions
- Drug: Candesartan
- Candesartan 8 mg/day
- Drug: Ramipril
- ramipril 1.25 mg/day
Arms, Groups and Cohorts
- No Intervention: Control group
- No intervention
- Active Comparator: Candesartan
- Candesartan 8 mg/day
- Active Comparator: Ramipril
- Ramipril 1.25 mg/day
Clinical Trial Outcome Measures
Primary Measures
- Change in Fibroscan or APRI score
- Time Frame: 6 months
- Change in Fibroscan or APRI score
Participating in This Clinical Trial
Inclusion Criteria
- chronic hepatitis C Exclusion Criteria:
- Acute hepatitis – Thalassemia
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Sherief Abd-Elsalam
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine – Tanta University
- Overall Official(s)
- Gamal El-azab, Prof, Principal Investigator, Clinical pharmacy Department- Tanta University
- Tarek Mostafa, Prof, Study Director, Cardiology Department- Tanta University
- Gamal Badra, Prof, Study Chair, National Hepatology Institute – Egypt
- Abeer El-Motwally, Msc, Study Chair, Clinical pharmacy Department-Tanta University
- Overall Contact(s)
- Sherief Abd-Elsalam, Ph D, 00201147773440, sheriefabdelsalam@yahoo.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.